Thermo Fisher Scientific Inc.: Our Calculation Of Intrinsic Value

Image Source: Unsplash
 

Each week we run a DCF (Discounted Cash Flow) model on a company from our watchlist. This week’s pick: Thermo Fisher Scientific Inc. (TMO).
 

Profile

Thermo Fisher Scientific is a global leader in life sciences tools, diagnostics, and laboratory services, serving pharmaceutical, biotechnology, academic, and healthcare customers worldwide. The company operates through a diversified portfolio spanning analytical instruments, specialty diagnostics, reagents, consumables, and contract research services. Its scale, recurring revenue base, and deep customer integration create durable competitive advantages, while disciplined capital allocation and steady end-market demand support consistent free cash flow generation across economic cycles.
 

DCF Analysis

Inputs

Discount Rate: 10%
Terminal Growth Rate: 3%
WACC: 10%

Forecasted Free Cash Flows

2025: $6.8 → PV: $6.2
2026: $7.1 → PV: $5.9
2027: $7.4 → PV: $5.6
2028: $7.7 → PV: $5.3
2029: $8.0 → PV: $5.0

Total Present Value of FCFs = $28.0B

Terminal Value Calculation

Using the perpetuity growth model with 2029 FCF = $8.0B:

TV = (8.0 × 1.03) ÷ (0.10 − 0.03) = $117.7B

Present Value of Terminal Value:

PV(TV) = 117.7 ÷ (1.10)^5 = $73.1B

Enterprise Value

Enterprise Value = $28.0B + $73.1B = $101.1B

Net Debt

Cash & Equivalents: ~$5.3B
Total Debt: ~$35.7B

Net Debt ≈ $30.4B

Equity Value & Per-Share Value

Equity Value: $101.1B − $30.4B = $70.7B
Shares Outstanding: ~378M

Intrinsic Value per Share ≈ $187
 

Conclusion

DCF Value: ~$187
Current Price: ~$527
Margin of Safety: –65%

Thermo Fisher remains a high-quality life sciences franchise with strong competitive positioning, diversified end-markets, and a large base of recurring and consumable-driven revenue. Its ability to generate steady free cash flow through economic cycles supports long-term shareholder value creation.

However, under a standardized DCF framework using a 10% discount rate and 3% terminal growth, the current market price implies expectations well above conservative intrinsic value. The valuation reflects assumptions around sustained mid-single-digit growth, margin durability, and continued leadership in life sciences tools and services.

For long-term investors, TMO represents a durable compounder benefiting from structural demand in healthcare and biotechnology. At today’s valuation, however, the stock offers limited margin of safety, suggesting that future returns are likely to depend more on business execution and end-market growth than on valuation expansion.

---

More By This Author:

Westlake Chemical Partners LP - Deep Value In The Chemical Infrastructure Sector
Our Calculation Of Intrinsic Value: The Walt Disney Company
Cricut, Inc.: Deep Value Consumer Hardware/Software Ecosystem